Cross-Sector entity
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Novartis, the most common co-covered peer. Each carries 4 original sources on average. We currently track 1 Cross-Sector story that mention ProstACT, all published on March 10, 2026.
1 verified story tracked
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Novartis, the most common co-covered peer. Each carries 4 original sources on average. We currently track 1 Cross-Sector story that mention ProstACT, all published on March 10, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ProstACT. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected interim efficacy data from the larger global patient cohort.
Primary Objectives Met
Announcement that Part 1 successfully validated safety and dosimetry profiles.
Enrollment Milestone
Completion of patient enrollment for the Part 1 SELECT lead-in phase.
Study Initiation
Launch of the ProstACT Global Phase 3 study for mCRPC.
Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Source: sydneysun.com · wallstreet-online.de
